Clinical trials need help!
Failure of One-Drug-Fits-All
Several potential effective drugs have been abandoned by the pharmaceutical companies due to problems related to clinical trials.
Unscalable
Per year, just the top four pharmaceutical companies spend over 400M€ in screening for Alzheimer’s clinical trials.
Patient Invasive
90% of initially enrolled patients drop out of the clinical trials due to issues with invasiveness and inconvenience of screening procedures (PET and lumbar puncture).
Inefficient
From the patients that are screened 80% are excluded for not fitting the trial, after being subjected to various invasive, unconfortable, risky procedures.
About us
How can we help?
Stratifying and screening patients in Alzheimer’s clinical trials in the right way.
• Inexpensive: 40% less cost
• Scalable: 70% less time
• Patient-friendly: Non-invasive
Team
Joana S. Paiva
CTO
Inventor, scientist, Professor in Physics and Biomedical and Physics engineer
Mehak Mumtaz
COO
Personalized medicine expert and PhD turned strategic consultant to C-Level leaders
Mentors & Advisors
Jorge Fernández García
Mentor & Advisor
EIT Health Director of Innovation, more than 18 years of experience in healthcare and life sciences
João Paulo Cunha
Mentor & Advisor
Innovator, inventor, passionate Professor of Bioengineering. Proud founder/mentor of 6 startups with tech from his lab, and counting
Pedro Jorge
Advisor
Renowned scientist in Photonics with vast technology transfer experience in optical fibre sensing technology, coordinator of more than 18 projects
Leveraging machine learning to drastically reduce the cost and time of drug discovery.
Awards
News
Coverage of iLoF by the Portuguese press
Altice Innovation Award media coverage
